Figure 2

Figure 2

Drug library screening to identify compounds affecting cardiomyocyte viability. Schematic overview of the drug library screen. HL-1 cells were plated with a drug library consisting of 689 FDA-approved compounds. Cells were exposed to hypoxia-reoxygenation for a viability dropout screen. As the readout, cellular viability was measured with CTG assays. (b) Effect of hypoxia-reoxygenation on the viability of DMSO-treated control cells (22% reduction in relative viability (P < 0.001)). (c) Scatter plot of DMSO-normalized relative viability values in normoxia vs. hypoxia-reoxygenation for each drug concentration. Correlation curve depicts the linear model of the correlation of the values between treatments. Horizontal line depicts the average viability of DMSO-treated cells in hypoxia-reoxygenation. Significant viability-improving effects are depicted with red dots for the maximally effective drug concentrations. The dot representing gefitinib is indicated in blue.